Cargando…
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial
BACKGROUND: Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study. AIMS: To study the associations between changes in body weight (intentional or unintentional) with subsequent...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442423/ https://www.ncbi.nlm.nih.gov/pubmed/34521390 http://dx.doi.org/10.1186/s12933-021-01382-8 |
_version_ | 1783753005166755840 |
---|---|
author | Ferreira, João Pedro Rossignol, Patrick Bakris, George Mehta, Cyrus White, William B. Zannad, Faiez |
author_facet | Ferreira, João Pedro Rossignol, Patrick Bakris, George Mehta, Cyrus White, William B. Zannad, Faiez |
author_sort | Ferreira, João Pedro |
collection | PubMed |
description | BACKGROUND: Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study. AIMS: To study the associations between changes in body weight (intentional or unintentional) with subsequent outcomes. METHODS: The EXAMINE trial included 5380 patients with T2D and a recent acute coronary syndrome, who were randomized to alogliptin or placebo. Time-updated Cox models and mixed effects models were used to test the associations between changes in body weight and subsequent outcomes over a median follow-up of 1.6 (1.0–2.1) years. RESULTS: During the post-randomization follow-up period, 1044 patients (19.4%) experienced a weight loss ≥ 5% of baseline weight, 2677 (49.8%) had a stable weight, and 1659 (30.8%) had a ≥ 5 % weight gain. Patients with weight loss were more frequently women and had more co-morbid conditions. In contrast, patients who gained ≥ 5% weight were more frequently men with less co-morbid conditions. A weight loss ≥ 5% was independently associated with a higher risk of subsequent adverse outcomes, including all-cause mortality: adjusted HR (95% CI) = 1.79 (1.33–2.42), P < 0.001. Similar associations were found for cardiovascular mortality, the composite of cardiovascular mortality or heart failure hospitalization, and the primary outcome. A weight gain ≥ 5% was independently associated with an increase in the risk of subsequent cardiovascular mortality or heart failure hospitalization only: adjusted HR (95% CI) = 1.34 (1.02–1.76), P = 0.033. CONCLUSIONS: In patients with T2D who had a recent ACS/MI, a ≥ 5% loss of body weight was associated with a higher risk of subsequent cardiovascular events and mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01382-8. |
format | Online Article Text |
id | pubmed-8442423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84424232021-09-15 Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial Ferreira, João Pedro Rossignol, Patrick Bakris, George Mehta, Cyrus White, William B. Zannad, Faiez Cardiovasc Diabetol Original Investigation BACKGROUND: Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study. AIMS: To study the associations between changes in body weight (intentional or unintentional) with subsequent outcomes. METHODS: The EXAMINE trial included 5380 patients with T2D and a recent acute coronary syndrome, who were randomized to alogliptin or placebo. Time-updated Cox models and mixed effects models were used to test the associations between changes in body weight and subsequent outcomes over a median follow-up of 1.6 (1.0–2.1) years. RESULTS: During the post-randomization follow-up period, 1044 patients (19.4%) experienced a weight loss ≥ 5% of baseline weight, 2677 (49.8%) had a stable weight, and 1659 (30.8%) had a ≥ 5 % weight gain. Patients with weight loss were more frequently women and had more co-morbid conditions. In contrast, patients who gained ≥ 5% weight were more frequently men with less co-morbid conditions. A weight loss ≥ 5% was independently associated with a higher risk of subsequent adverse outcomes, including all-cause mortality: adjusted HR (95% CI) = 1.79 (1.33–2.42), P < 0.001. Similar associations were found for cardiovascular mortality, the composite of cardiovascular mortality or heart failure hospitalization, and the primary outcome. A weight gain ≥ 5% was independently associated with an increase in the risk of subsequent cardiovascular mortality or heart failure hospitalization only: adjusted HR (95% CI) = 1.34 (1.02–1.76), P = 0.033. CONCLUSIONS: In patients with T2D who had a recent ACS/MI, a ≥ 5% loss of body weight was associated with a higher risk of subsequent cardiovascular events and mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01382-8. BioMed Central 2021-09-14 /pmc/articles/PMC8442423/ /pubmed/34521390 http://dx.doi.org/10.1186/s12933-021-01382-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Investigation Ferreira, João Pedro Rossignol, Patrick Bakris, George Mehta, Cyrus White, William B. Zannad, Faiez Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial |
title | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial |
title_full | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial |
title_fullStr | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial |
title_full_unstemmed | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial |
title_short | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial |
title_sort | body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the examine trial |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442423/ https://www.ncbi.nlm.nih.gov/pubmed/34521390 http://dx.doi.org/10.1186/s12933-021-01382-8 |
work_keys_str_mv | AT ferreirajoaopedro bodyweightchangesinpatientswithtype2diabetesandarecentacutecoronarysyndromeananalysisfromtheexaminetrial AT rossignolpatrick bodyweightchangesinpatientswithtype2diabetesandarecentacutecoronarysyndromeananalysisfromtheexaminetrial AT bakrisgeorge bodyweightchangesinpatientswithtype2diabetesandarecentacutecoronarysyndromeananalysisfromtheexaminetrial AT mehtacyrus bodyweightchangesinpatientswithtype2diabetesandarecentacutecoronarysyndromeananalysisfromtheexaminetrial AT whitewilliamb bodyweightchangesinpatientswithtype2diabetesandarecentacutecoronarysyndromeananalysisfromtheexaminetrial AT zannadfaiez bodyweightchangesinpatientswithtype2diabetesandarecentacutecoronarysyndromeananalysisfromtheexaminetrial |